Featured Research

from universities, journals, and other organizations

Current Research Offers Hope For Liver Cancer Patients

Date:
July 3, 2000
Source:
Adelaide University
Summary:
A medical team from Adelaide University in South Australia has begun final trials on a new and promising treatment for liver cancer. The surgeons are tackling the liver tumours with electrolysis, with positive results.

Cancers of the colon and rectum are among the most common. While early diagnosis offers good prospects for their treatment, many are diagnosed at a late stage. By then, a colo-rectal cancer which is in itself treatable has often spread to the liver.

Cancers of the liver are generally incurable. Only about 20% of livers diseased with tumours can be treated at present, and even then only with difficulty. Because the liver is essential for life and health, surgery is impossible when it involves the removal of excessive amounts of liver tissue. Transplants usually can not be considered.

A medical research team from Adelaide University has begun final trials on a new and promising treatment for these liver tumours. The surgeons, based in the Department of Surgery at Adelaide’s Queen Elizabeth Hospital, are now tackling liver tumours with electrolysis.

Electrolysis involves passing an electric current through the liver, a process that produces chemical and physical changes. Electrolysis can split water into oxygen and hydrogen, or produce strong acids and alkalis from neutral solutions.

The surgical team has developed techniques for inserting electrodes into a liver tumour and using low voltage to move ions between them, liberating toxic substances that destroy the tumour chemically. The current can be controlled to deliver a predictable dose-dependent response over time, and even very large tumours can be treated.

"The tumour isn’t burned,’ explained Research Assistant Ms Paula Baxter, ‘the current is too low. We have an apparently safe process of destroying the tumour with the chemical action of electrolysis."

The technology has been developed conjointly with the University of Leicester. Over the last 4 years, 5 doctors from Leicester have been collaborating with the Adelaide team, led by Professor Guy Maddern.

"This is a technique and a technology that has not been used anywhere else in the world for this sort of condition," said Professor Maddern. "It is now being published in recognised journals and we hope that if we can get it working efficiently, it will be picked up around the world," he said.

"By placing the electrodes very carefully into the tumour, we hope to treat patients without resorting to major surgery,’ said Dr Guy Finch. ‘We might even see the day when electrodes are left in the liver for several weeks, and patients come into the clinic for several sessions of treatment until the tumour is destroyed. It would be simple to manage, causing little discomfort and minimal disruption to patients’ daily lives," he said.

Following initial work on animals, a pilot study on five patients showed complete tumour destruction in all cases. That trial led to the use of electrolysis to treat three further patients with inoperable liver tumours. A surgical procedure on one patient 12 months later showed no trace of the original tumour, and that patient is now at 20 months follow up. The other two patients are currently at 14 and 12 months follow up, and neither shows any evidence of liver tumours.

"The patients we’ve treated to date have all gone well," said Professor Maddern. "They continue to be so, and some of them are now alive and well at a period of time greater than twelve months," he said.

"I think that this is not going to be a cure-all for all people," said Professor Maddern, "but I think for those who have cancers in the liver that are considered to be inoperable, this makes the patients potentially operable," he said.

"If in the future the disease returns, after what we thought was a curative operation, we may well be able to treat these patients without the need for surgery," said Professor Maddern. "We expect that the technique will improve a lot over the next 12 months."

For any new form of cancer therapy to become accepted in clinical practice, it must be shown to improve patient survival. This is best shown by a 5-year follow up of a controlled clinical trial of patients with inoperable disease.

The Department of Surgery is very keen to have any patients with known liver cancers referred to them to be assessed for their suitability for electrolytic treatment.

Arrangements can be made directly with Professor Maddern’s receptionist at Adelaide's Queen Elizabeth Hospital -- ph (618) 8222 6750

- Rob Morrison

Photos of operating team, electrolysis, operations available at:

http://www.adelaide.edu.au/PR/media_photos/

Contacts: Professor Guy Maddern, Dr Guy Finch, (618) 8222 6750


Story Source:

The above story is based on materials provided by Adelaide University. Note: Materials may be edited for content and length.


Cite This Page:

Adelaide University. "Current Research Offers Hope For Liver Cancer Patients." ScienceDaily. ScienceDaily, 3 July 2000. <www.sciencedaily.com/releases/2000/06/000629205926.htm>.
Adelaide University. (2000, July 3). Current Research Offers Hope For Liver Cancer Patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2000/06/000629205926.htm
Adelaide University. "Current Research Offers Hope For Liver Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2000/06/000629205926.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins